La Jolla Institute for Immunology and RevolKa started a Research Collaboration
18 Abril 2024 - 7:30PM
Business Wire
LJI and RevolKa will Research Nex-gen Vaccine
Antigens by using AI-driven Protein Engineering Platform
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a
venture-backed biotech company providing a game-changing protein
engineering technology platform and La Jolla Institute for
Immunology (LJI) (Erica Saphire, President & CEO) agreed to
start a research collaboration to create antigens for the
next-generation vaccines to deliver innovative solutions to unmet
medical need in infectious diseases. RevolKa has a robust directed
protein evolution technology integrated with artificial
intelligence (AI), called aiProtein®. LJI and RevolKa will
synergize LJI’s deep knowledge of immunology and RevolKa’s power of
AI-driven protein engineering. Details of this collaboration and
financial terms were not disclosed.
About aiProtein® Technology
RevolKa’s proprietary technology, aiProtein® is an AI-assisted
directed evolution of proteins. Naturally occurring protein is a
linear polymer of amino acids and their derivatives, which folds
into a tertial structure through internal complex atomic
interactions to show biological function. Proteins have evolved to
biologically functional molecules over hundreds of millions of
years. The relationship between protein sequence, structure, and
function in those highly functioned molecules remains poorly
understood to rationally design a protein sequence for a particular
function. Our AI engine is trained with sequence-function
relationship data to statistically predict sequences for an evolved
protein function. Furthermore, aiProtein® can evolve more than two
functions simultaneously. This technology is a powerful and
cost-effective tool for the creation of novel and highly-optimized
proteins for pharmaceutical and industrial uses.
About RevolKa Ltd.
RevolKa is a venture-backed biotechnology company founded in
April 2021 by academic and industry experts in biotechnology and
artificial intelligence. Our mission is to create novel proteins
useful for therapeutics and industries by using our own proprietary
technology platform, aiProtein® to contribute to human well-being.
The name "RevolKa" is derived from the Latin word for evolution,
"evolutio” and the Ainu (an indigenous Japanese people) word for
raise, “reska”. RevolKa’s headquarters are located in Tokyo, Japan
with laboratories located in Sendai. The company’s investors
include D3 LLC, DEEPCORE Inc., Tohoku University Venture Partners,
and SBI investment Co., Ltd. For more information, visit
https://www.revolka.com/en/.
About La Jolla Institute for Immunology
The La Jolla Institute for Immunology is dedicated to
understanding the intricacies and power of the immune system to
that we may apply to that knowledge to promote human health and
prevent a wide range of diseases. Since its founding in 1988 as an
independent, nonprofit research organization, the Institute has
made numerous advances leading towards its goal: Life without
Disease®. For more information, visit
https://www.lji.org/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240408374466/en/
RevolKa Ltd. Ayumi Iwase Email: info@revolka.co.jp TEL:
+81-3-5990-9858